Online inquiry

IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6257MR)

This product GTTS-WQ6257MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6257MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4086MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ10610MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ9035MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ1982MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ9494MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ7922MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ12204MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ13188MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW